Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Hepatology

Volumn 58, Issue 6, 2013, Pages 1918-1929

  Fried, Michael W ^a   Buti, Maria ^b   Dore, Gregory J ^c,d   Flisiak, Robert ^e   Ferenci, Peter ^f   Jacobson, Ira ^g   Marcellin, Patrick ^h   Manns, Michael ⁱ   Nikitin, Igor ^j   Poordad, Fred ^k   Sherman, Morris ^l   Zeuzem, Stefan ^m   Scott, Jane ⁿ   Gilles, Leen ^o   Lenz, Oliver ^o   Peeters, Monika ^o   Sekar, Vanitha ^p   De Smedt, Goedele ^o   Beumont Mauviel, Maria ^o  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h BEAUJON HOSPITAL   (France)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^l TORONTO GENERAL HOSPITAL   (Canada)

^m UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁿ Janssen Global Services   (United Kingdom)

^o JANSSEN RESEARCH FOUNDATION   (Belgium)

^p JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SIMEPREVIR; ALPHA INTERFERON; FUSED HETEROCYCLIC RINGS; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; SULFONAMIDE; VIRUS RNA;

ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EYE DISEASE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INFESTATION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SIDE EFFECT; TREATMENT DURATION; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84888295678     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26641     Document Type: Article

References (25)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
2. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012;32(Suppl 1):88-102.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
4. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
5. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
6. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012;142:1314-1323.
7. Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French Early Access Program (ANRS CO20-CUPIC) [abstract]. J Hepatol 2012;56:8.
8. Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, van 't Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138:913-921.
9. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012;56:1247-1253.
10. Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009;53:1377-1385.
11. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002.
12. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-1278.
13. Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011;16:1021-1033.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
15. Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508.
16. Lenz O, Verbinnen T, Lin T-I, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010;54:1878-1887.
17. Clark PJ, Thompson AJ. Host genomics and HCV treatment response. J Gastroenterol Hepatol 2012;27:212-222.
18. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
19. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-1345.
20. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104.
21. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
22. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-129.
23. Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study. Hepatology 2012;56:884-893.
24. Sulkowski MS, Ferenci P, Emanoil C, Asselah T, Caruntu F, Lalezari J, et al. SILEN-C1: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV infection. Hepatology 2009;50:2A.
25. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A.In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Poster 278 presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, October 29-November 2, 2010.